Garry Arthur Neil, CEO and Chairman of the Board at Avalo Therapeutics, Inc. (AVTX), bought 2,083 shares at $4.42 ($9K) on 2022-12-09, disclosed to the SEC on 2022-12-12.
Open-market purchase of $9k AVTX by CEO and Chairman of the Board. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CERC | BUY | 2021-06-14 | $8K | — | Filing → |
| CERC | BUY | 2020-12-14 | $8K | — | Filing → |
| CERC | BUY | 2020-06-11 | $4K | — | Filing → |